Capsaicin patch license extension application withdrawn
21st March 2012
Astellas Pharma has withdrawn its application to the European Medicines Agency (EMA) for a license extension for Qutenza® (capsaicin 8% transdermal patch). The application was to extend the marketing authorization for Qutenza® to all adult patients with exclusion of patients with pain caused by diabetes.
The withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP)'s view that the data provided would not allow the committee to conclude on a positive benefit-risk balance.
Qutenza® continues to be authorized for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults either alone or in combination with other medicinal products for pain.
- Cochrane review: Corticosteroids for the management of cancer-related pain in adults
- MHRA: Tramadol 50mg capsules batch recall
- Never Event list 2015/2016
- Codeine for cough and cold contra-indicated for children under 12 years
- Methylnaltrexone indication extended
- Prucalopride indication extended
- Cochrane review: Pharmacological interventions for pain in children and adolescents with life-limiting conditions
- Legislation changes for controlled drugs
- Cochrane review: Buprenorphine for treating cancer pain
- New PO magnesium product for hypomagnesaemia